Jacqueline Tate

Dr. Jacqueline Tate


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
JTJacqueline Tate
Jacqueline Tate
ABAnthony H Burton
Anthony H Burton
CBCynthia Boschi-Pinto
Cynthia Boschi-Pinto
DSDuncan Steele
Duncan Steele
JDJazmin Duque
Jazmin Duque
UPUmesh D Parashar
Umesh D Parashar
WHO recommends routine use of rotavirus vaccines in all countries, particularly in those with high mortality attributable to diarrhoeal diseases. To establish the burden of life-threatening rotavirus disease before the introduction of a rotavirus vaccine, we aimed to update the estimated number of deaths worldwide in children younger than 5 years due to diarrhoea attributable to rotavirus infection. We used PubMed to identify studies of at least 100 children younger than 5 years who had been admitted to hospital with diarrhoea. Additionally, we required the studies to have a data collection midpoint of the year 2000 or later, to be done in full-year increments, and to assesses diarrhoea attributable to rotavirus with EIAs or polyacrylamide gel electrophoresis. We also included data from countries that participated in the WHO-coordinated Global Rotavirus Surveillance Network (consisting of participating member states during 2009) and that met study criteria. For countries that have introduced a rotavirus vaccine into their national immunisation programmes, we excluded data subsequent to the introduction. We classified studies into one of five groups on the basis of region and the level of child mortality in the country in which the study was done. For each group, to obtain estimates of rotavirus-associated mortality, we multiplied the random-effect mean rotavirus detection rate by the 2008 diarrhoea-related mortality figures for countries in that group. We derived the worldwide mortality estimate by summing our regional estimates. Worldwide in 2008, diarrhoea attributable to rotavirus infection resulted in 453,000 deaths (95% CI 420,000-494,000) in children younger than 5 years-37% of deaths attributable to diarrhoea and 5% of all deaths in children younger than 5 years. Five countries accounted for more than half of all deaths attributable to rotavirus infection: Democratic Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan; India alone accounted for 22% of deaths (98,621 deaths). Introduction of effective and available rotavirus vaccines could substantially affect worldwide deaths attributable to diarrhoea. Our new estimates can be used to advocate for rotavirus vaccine introduction and to monitor the effect of vaccination on mortality once introduced.

1 August 2009 in Pediatrics
Verified
Journal Article
Closed access
PDF file
JTJacqueline Tate
Jacqueline Tate
CPCatherine A. Panozzo
Catherine A. Panozzo
DPDaniel C. Payne
Daniel C. Payne
MPManish M. Patel
Manish M. Patel
MCMargaret M. Cortese
Margaret M. Cortese
UPUmesh D. Parashar
Umesh D. Parashar
BACKGROUND: In 2006, routine immunization of US infants against rotavirus was initiated. We assessed national, regional, and local trends in rotavirus testing and detection before and after vaccine introduction. METHODS: We examined data for July 2000 through June 2008 from a national network of ∼70 US laboratories to compare geographical and temporal aspects of rotavirus season timing and peak activity. To assess trends in rotavirus testing and detection, we restricted the analyses to 33 laboratories that reported for ≥26 weeks per season from 2000 to 2008. RESULTS: Nationally, the onset and peak of the 2007–2008 rotavirus season were delayed 15 and 8 weeks, respectively, compared with prevaccine seasons from 2000–2006. Delays were observed in each region. The 2007–2008 rotavirus season lasted 14 weeks compared with a median of 26 weeks during the prevaccine era. Of 33 laboratories, 32 reported fewer positive results and a lower proportion of positive test results in 2007–2008 compared with the median in 2000–2006, with a 67% decline in the number and a 69% decline in the proportion of rotavirus-positive test results. The proportion of positive test results in 2007–2008 compared with the median in 2000–2006 declined >50% in 79% of the laboratories and >75% in 39% of the laboratories. CONCLUSIONS: The 2007–2008 US rotavirus season seems substantially delayed, shorter, and diminished in magnitude compared with seasons before vaccine implementation. The extent of change seems greater than expected on the basis of estimated vaccine coverage, suggesting indirect benefits to unvaccinated individuals. Monitoring in future seasons is needed to confirm these trends.

1 January 2011 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JTJacqueline Tate
Jacqueline Tate
MCMargaret M. Cortese
Margaret M. Cortese
DPDaniel C. Payne
Daniel C. Payne
ACAaron T. Curns
Aaron T. Curns
CYCatherine Yen
Catherine Yen
UPUmesh D. Parashar
Umesh D. Parashar
Rotavirus vaccine was recommended for routine use in US infants in 2006. Before the introduction of vaccine, rotavirus was the most common cause of severe gastroenteritis in children <5 years of age in the United States. We reviewed published data to summarize the US experience during the first 3 years of its rotavirus vaccination program. Rotavirus seasons have been delayed and diminished in magnitude during the postvaccine era compared with the prevaccine era. Hospitalizations, emergency department visits, and outpatient visits due to gastroenteritis have declined dramatically in children < 5 years of age including in children age-ineligible to have received vaccine, suggesting indirect benefits of vaccination. Rotavirus vaccine has been widely accepted by pediatricians. Vaccine coverage is steadily increasing but remains lower than coverage levels of other routine infant immunizations. The implementation of routine childhood immunization against rotavirus has rapidly and dramatically reduced the large health burden of rotavirus gastroenteritis in US children. Continued monitoring of rotavirus diarrhea is needed to determine if immunity wanes as vaccinated children get older and to better quantify the indirect benefits of vaccination. Ongoing surveillance will also enable monitoring of the long-term impact of vaccination on rotavirus epidemiology.

1 January 2011 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JTJacqueline Tate
Jacqueline Tate
JMJeffry D. Mutuc
Jeffry D. Mutuc
CPCatherine A. Panozzo
Catherine A. Panozzo
DPDaniel C. Payne
Daniel C. Payne
MCMargaret M. Cortese
Margaret M. Cortese
UPUmesh D. Parashar
Umesh D. Parashar
Following implementation of the rotavirus vaccination program in 2006, rotavirus activity in the United States declined dramatically in 2007–2008 but increased slightly in 2008–2009, despite greater vaccine uptake. To further evaluate impact of the vaccine program, we assessed trends in rotavirus testing and detection during 2009–2010. We examined rotavirus testing data from July 2000 to June 2010 from the National Respiratory and Enteric Viruses Surveillance System to compare rotavirus season timing and peak activity in the pre- and postvaccine introduction eras. Rotavirus season onset was defined as the first of 2 consecutive weeks during which the percentage of specimens testing positive for rotavirus was ≥10%. To assess trends in rotavirus testing and detection, we restricted the analyses to 25 laboratories that reported for ≥26 weeks per season from 2000 to 2010. During 2009–2010, the threshold for the start of the rotavirus season was never achieved nationally or in the North, Midwest, or West. Activity in the South met this threshold but the season duration was substantially shorter and of lower magnitude than in all previous pre- and postvaccine introduction seasons. Nationally and within each region, the peak week was more delayed and the peak proportion of positive tests was substantially lower than all previous seasons. The total number of tests performed declined by 23%, and the number of positive tests declined by 86%. Rotavirus activity was substantially diminished during the 2009–2010 rotavirus season compared with the prevaccine baseline and the 2 previous postvaccine introduction seasons. These sustained declines over 3 rotavirus seasons reaffirm the health benefits of the US rotavirus vaccination program.

15 May 2009 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
JTJacqueline Tate
Jacqueline Tate
MBMichel L. Bunning
Michel L. Bunning
LLLisa Lott
Lisa Lott
XLXiaoyan Lu
Xiaoyan Lu
JSJohn Su
John Su
MWMarc-Alain Widdowson
Marc-Alain Widdowson
BackgroundIn 2007, a US Air Force training facility reported a cluster of severe respiratory illnesses associated with a rare human adenovirus (Ad) s

1 May 2008 in Pediatrics
Verified
Journal Article
Closed access
PDF file
JTJacqueline Tate
Jacqueline Tate
LSLone Simonsen
Lone Simonsen
CVCecile Viboud
Cecile Viboud
CSClaudia Steiner
Claudia Steiner
MPManish M. Patel
Manish M. Patel
UPUmesh D. Parashar
Umesh D. Parashar
OBJECTIVES. In 2006, a new rotavirus vaccine was recommended for routine immunization of US infants. Because a previous rotavirus vaccine was withdrawn in 1999 after it was associated with intussusception, monitoring for this adverse event with the new vaccine is important. The objectives of this study were to assess intussusception hospitalizations trends among US infants for 1993 to 2004; provide estimates of hospitalization rates for intussusception for 2002–2004; and assess variations in background rates by age, race/ethnicity, and surgical management. METHODS. By using the Healthcare Cost and Utilization Project9s State Inpatient Database that captures US hospital discharges from 16 states representing 49% of the birth cohort during 1993–2004 and from 35 states representing 85% of the birth cohort in 2002–2004, we examined hospitalizations among infants (<12 months of age) with an International Classification of Disease, Ninth Revision, Clinical Modification code for intussusception (560.0). Incidence rates were calculated by using census data, and rate ratios with 95% confidence intervals were calculated by using Poisson regression data. RESULTS. Annual intussusception hospitalization rates declined 25% from 1993 to 2004 but have remained stable at ∼35 cases per 100000 infants since 2000. Rates were very low for infants younger than 9 weeks (<5 per 100000) then increased rapidly, peaking at ∼62 per 100000 at 26 to 29 weeks, before declining gradually to 26 per 100000 at 52 weeks. Compared with rates among non-Hispanic white infants (27 per 100000), rates were greater among non-Hispanic black infants (37 per 100000) and Hispanic infants (45 per 100000); however, rates did not differ by race/ethnicity for infants who were younger than 16 weeks. CONCLUSIONS. This assessment of US hospitalizations provides up-to-date and nationally representative prevaccine rates of intussusception. Because rates varied almost 12-fold by week of age and to a lesser extent by race/ethnicity during the age of vaccination, adjusting baseline rates to reflect the demographics of the vaccinated population will be crucial for assessing risk for intussusception after rotavirus vaccination.